Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells
- 275 Downloads
Microtubule-stabilizing agents are an important class of anticancer compounds. Peloruside A and laulimalide bind to a different site on the microtubule to taxoid site drugs such as paclitaxel (Taxol®), docetaxel (Taxotere®), ixabepilone (Ixempra®), the epothilones, and discodermolide. The purpose of this study was to examine the synergistic interactions of these drugs when given in combination in relation to the differences in their binding sites on the microtubule.
Human ovarian carcinoma cells (1A9 cells) and murine T cells were treated with different combinations of microtubule-stabilizing or destabilizing agents. The compounds were given individually and in combination, and the antiproliferative activity was assessed to calculate a combination index (CI) from the equation: CI = D 1/Dx 1 + D 2/Dx 2 in which D 1 and D 2 are the concentrations of drug 1 and drug 2 that when given together give the same response as drug 1 and 2 alone (Dx 1 and Dx 2). Thus, a CI value of less than 1.0 indicates a synergistic effect between the two drugs in which the response to the two drugs given together is greater than the additive response of the two drugs if given on their own.
As anticipated from previous in vitro studies, peloruside A and laulimalide did not synergize with each other. They also failed to synergize with the microtubule-destabilizing agents vinblastine and 2-methoxyestradiol. Peloruside A and laulimalide did, however, synergize with the epothilones, as had been previously shown, but not with docetaxel or discodermolide.
Combining two microtubule-targeting agents with different binding sites does not guarantee a synergistic interaction in cells, and additional factors are likely to be involved. This study highlights the importance of preclinical testing of actual combinations of drugs before proceeding into clinical trials.
KeywordsAnticancer drug Combination therapy Laulimalide Microtubule-targeting agent Peloruside A Synergy
Carboxyfluorescein succinimidyl ester
Multiple drug resistance
We would like to thank Kelly Bargh and Dora Leahy for expert technical assistance and Guy Naylor and Jonathan Singh for preparation of the chemical structures in Fig. 1. This work was supported in part by the Cancer Society of New Zealand, the Genesis Oncology Trust, the Wellington Medical Research Foundation, the New Zealand Foundation of Research, Science, and Technology, and Victoria University of Wellington.
- 1.Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26:468–473PubMedCrossRefGoogle Scholar
- 6.Campone M, Blasinska-Morawiek M, Tekiela A, Koralewski P, Pouget JC, Douville I, Brandely M (2009) Phase II study of vinerelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 63:937–943PubMedCrossRefGoogle Scholar
- 7.Chan A, Andreae P, Northcote PT, Miller JH (2010) Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7. Invest New Drugs. doi: 10.1007/s10637-010-9398-2
- 10.Crume KP, Miller JH, La Flamme AC (2007) Peloruside A, an anti-mitotic agent, specifically decreases TNF-α production by LPS-stimulated murine macrophages. Exp Biol Med 232:607–613Google Scholar
- 16.Gertsch J, Meier S, Müller M, Altmann KH (2009) Differential effects of natural product microtubule stabilizers on microtubule assembly: Single agent and combination studies with Taxol, epothilone B, and discodermolide. Chem Biol Chem 10:166–175Google Scholar
- 19.Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ (2006) Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 70:1555–1564PubMedCrossRefGoogle Scholar
- 29.Miller VA (1997) Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. Semin Oncol 24(Suppl 14):S14-15–S14-17Google Scholar
- 33.Pryor DE, O’Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41:9109–9115PubMedCrossRefGoogle Scholar
- 38.Wilmes A, Rawson P, Peng L, McLauchlan D, Northcote PT, Jordan TW, Miller JH (2010) Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells. Invest New Drugs. doi: 10.1007/s10637-010-9387-5